Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01559142 |
|
Recruitment Status : Unknown
Verified April 2012 by JAROSLAW KIERKUS, Children's Memorial Health Institute, Poland.
Recruitment status was: Active, not recruiting
First Posted : March 21, 2012
Last Update Posted : April 4, 2012
|
Sponsor:
Children's Memorial Health Institute, Poland
Information provided by (Responsible Party):
JAROSLAW KIERKUS, Children's Memorial Health Institute, Poland
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The aim of the study is confirmation of efficacy of induction therapy with three doses of infliximab In patients with Crohn disease aged 7-17 years, and comparison of efficacy and safety of two regiment of maintenance therapy:
- Infliximab with immunomodulation
- Infliximab alone
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Crohn Disease | Drug: Infliximab with azathioprine (IIFX + AZA) Drug: Infliximab (IFX alone) | Phase 3 |
Show Detailed Description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Efficacy and Safety of Induction Therapy With Three Doses of Infliximab in Patients With Crohn Disease Aged 7-17 Years-multicenter Open Study. Efficacy and Safety of Two Regimens of Maintenance Therapy in Patients With Crohn Disease Aged 7-17 Years-multicenter Randomized Study |
| Study Start Date : | November 2008 |
| Estimated Primary Completion Date : | April 2012 |
| Estimated Study Completion Date : | December 2012 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Crohn disease
MedlinePlus related topics:
Crohn's Disease
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: IFX TG |
Drug: Infliximab with azathioprine (IIFX + AZA)
Infliximab with azathioprine during whole one year study |
| Active Comparator: IFX alone |
Drug: Infliximab (IFX alone)
Infliximab continuously; azathioprine stopped in 26 week |
Primary Outcome Measures :
- Clinical disease activity [ Time Frame: 14 week and one year ]
Secondary Outcome Measures :
- endoscopic disease activity [ Time Frame: 14 week and one year ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 7 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with severe Crohn disease (PCDAI in anamnesis more than 51 points), with PCDAI currently over 30 points, with no or loss of response for previous therapy (except biological agents). Patients may have active fistulas.
- Efficient methods of contraception in patients of childbearing potential during study period and six months after.
- Patients will be enrolled to Part B of the study whether they finish Part A with clinical remission or clinical response.
Exclusion Criteria:
- Hypersensitivity to infliximab
- Pregnancy and breastfeeding
- Active tuberculosis or other severe infection: sepsis, opportunistic infections, active CMV, yersinia pseudotuberculosis, pneumocystis carini, atypical mycobacteriosis
- VZV infection, hepatitis, pneumonia during 3 months before Day 0 of the study
- pancytopaenia and aplastic anemia
- moderate and severe heart insufficiency (NYHA class III/IV), or unstable coronary heart disease
- chronic pulmonary insufficiency, chronic renal insufficiency, chronic liver insufficiency
- HIV infection
- Presence of severe diseases of nervous system or severe endocrinological, hematological, psychiatric diseases.
- Demyelinisation syndrome or symptoms resembling Demyelinisation syndrome
- Malignancy or premalignant conditions during 5 years before Day 0 of the study.
- Severe infection currently present
- Malignancy currently present
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01559142
Locations
| Poland | |
| Department of Gastroenterology, Hepatology and Feeding Disorders | |
| Warsaw, Poland, 04-730 | |
Sponsors and Collaborators
Children's Memorial Health Institute, Poland
Investigators
| Principal Investigator: | Jaroslaw Kierkus, MD PhD | The Children's Memorial Institute |
| Responsible Party: | JAROSLAW KIERKUS, MD, PhD, Children's Memorial Health Institute, Poland |
| ClinicalTrials.gov Identifier: | NCT01559142 History of Changes |
| Other Study ID Numbers: |
IP CZD 2008-01-14 |
| First Posted: | March 21, 2012 Key Record Dates |
| Last Update Posted: | April 4, 2012 |
| Last Verified: | April 2012 |
Keywords provided by JAROSLAW KIERKUS, Children's Memorial Health Institute, Poland:
|
Crohn Disease infliximab azathioprine |
Additional relevant MeSH terms:
|
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases Infliximab Azathioprine Dermatologic Agents |
Gastrointestinal Agents Antirheumatic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |